Arkolith/Insider Trading/SNSE/Form 4

Colgan Erin

CHIEF FINANCIAL OFFICERSensei Biotherapeutics, Inc. (SNSE) · full profile →Form 4 · filed Feb 16, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 15, 2024Tax withholding(F)4K$0.79$3K67K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 15, 2024Grant(A)125K—$0125K
Feb 15, 2024Grant(A)94K—$094K

Transaction Codes

F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-004234) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML